Identifying inhibitors of protein–protein interactions is an ongoing challenge in the field of drug design, but the use of peptide fragments based on a known binding interface is showing promise.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fletcher, S. & Hamilton, A. D. Curr. Top. Med. Chem. 7, 922–927 (2007).
Robinson, J. A., Demarco, S., Gombert, F., Moehle, K. & Obrecht, D. Drug Discov. Today. 13, 944–951 (2008).
Pieraccini, S. et al. Nature Chem. 1, 642–648 10.1038/nchem.401(2009).
Banerjee, S., Wang, Z., Mohammad, M., Sarkar, F. H. & Mohammad, R. M. J. Nat. Prod. 71, 492–496 (2008).
Rubinstein, M. & Niv, M. Y. Biopolymers 91, 505–513 (2009).
Ofran, Y. & Rost, B. PLoS Comput. Biol. 3, 1169–1176 (2007).
Zhong, S., Macias, A. T. & MacKerell, A. D. Jr Curr. Top. Med. Chem. 7 63–82 (2007).
González-Ruiz, D. & Gohlke, H. Curr. Med. Chem. 13, 2607–25 (2006).
Che, Y., Brooks, B. R. & Marshall, G. R. J. Comput. Aided Mol. Des. 20, 109–130 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sackett, D., Sept, D. Making drug design second nature. Nature Chem 1, 596–597 (2009). https://doi.org/10.1038/nchem.427
Issue Date:
DOI: https://doi.org/10.1038/nchem.427